Formula I STAT Modulators for Specific STAT3 and STAT6 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with aberrantly elevated STAT3 and STAT6 activity, such as cancer and inflammatory diseases, lack effective modulators that can specifically target these proteins to inhibit their dysregulatory functions.
Innovation Solution
Development of compounds with specific structural Formula I that act as modulators of STAT3 and/or STAT6, inhibiting their activity and providing therapeutic benefits in conditions like cancer and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for conditions associated with elevated STAT3 and STAT6 activity, then current standard therapies can be applied, but effective specific modulation of STAT3 and STAT6 cannot be achieved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of compounds to specifically interact with STAT3 and STAT6. The compounds incorporate specific functional groups and molecular configurations that change the binding parameters to achieve high-affinity interaction with STAT proteins, thereby achieving reliable and specific modulation.
Solution Approach 2:
The patent uses compounds as intermediary substances that mediate between therapeutic agents and STAT3/STAT6 proteins. These compounds act as selective modulators that transmit the inhibitory signal specifically to STAT proteins, enabling effective treatment without affecting other signaling pathways.
2Adaptability or versatility
If broad-spectrum therapies are used to treat cancer and inflammatory conditions, then multiple conditions can be addressed, but specific inhibition of STAT3 and STAT6 is not achieved
Solution Approach 1:
The patent achieves universality by designing compounds that can inhibit both STAT3 and STAT6 through a unified molecular mechanism. The compounds possess structural features that allow them to bind to multiple STAT family members, providing multi-functional therapy for different conditions including cancer and inflammatory diseases.
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular regions that preferentially interact with STAT3 and STAT6 over other STAT members or unrelated proteins. The local structural features at specific positions in the molecule confer selective binding affinity, ensuring reliable inhibition of target STAT proteins while maintaining broad therapeutic applicability.
Data Source
AI summary
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.